ACE2 News and Research

RSS

Female reproductive organs not susceptible to direct SARS-CoV-2 infection

Researchers at the University in San Francisco, California, report that coronavirus disease 2019 (COVID-19) is unlikely to negatively impact on pregnancy-related outcomes such as premature birth, transmission to babies via breast milk, and infertility.

23 Jun 2020

First clinical trial in South Africa for Covid-19 vaccine begins

The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).

23 Jun 2020

SARS-CoV-2 induces broad T cell response in recovering patients

A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.

23 Jun 2020

Scientists create 'all-atom' model of SARS-CoV-2 spike protein

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease (COVID-19), an illness that has spread across the globe, infecting more than 9 million people. The novel coronavirus invades cells through "spike proteins," which sticks and binds itself to a host cell.

23 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Dire warning on contamination of water and COVID-19 spread

A recent report by scientists in the United Kingdom and Poland and published on the preprint server medRxiv in June 2020 describes the presence of stable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in water for up to 25 days, with the risk of infection by the contaminated water varying by the country’s environment.

22 Jun 2020

UAH researchers assess treatment efficacy of naturally occurring compounds against COVID-19

The Baudry Lab at The University of Alabama in Huntsville has identified 125 naturally occurring compounds that have a computational potential for efficacy against the COVID-19 virus from the first batch of 50,000 rapidly assessed by a supercomputer.

22 Jun 2020

Massive proteomics investigation of COVID-19 infection

Researchers from Germany and Switzerland revealed functional effects of individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins on cellular level after infection. They placed the findings into the context of host signaling pathways in order to identify vulnerable parts of the virus amenable to treatment. The study is currently available on the bioRxiv preprint server.

21 Jun 2020

Interesting study on which species may be infected by SARS-CoV-2

The team from the University of Cambridge and the Pirbright Institute found that the Spike protein on SARS-CoV-2 engages with the host cell receptor angiotensin-converting enzyme 2 (ACE2) across a wide range of animals, even though the Spike binding site shows a between-species variation in its amino acid composition.

21 Jun 2020

Promising candidate monoclonal antibodies show "exquisite potency" against SAR-CoV-2

Researchers at Columbia University, Dana-Farber Cancer Institute, and the National Institutes of Health have identified and characterized a range of monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

21 Jun 2020

Direct structural link between SARS-CoV-2 and essential fatty acid

Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.

21 Jun 2020

Balanced B and T cell response required to control SARS-CoV-2

A new study by researchers in the Netherlands and published on the preprint server bioRxiv in June 2020 describes the differences in T and B cell responses seen in patients with severe COVID-19.

21 Jun 2020

Blood types and COVID-19 risk confirmed

Blood type may play a pivotal role in driving disease severity among coronavirus disease (COVID-19) patients. Genetic analysis of COVID-19 patients has shown that people with blood type O seemed to be protected against severe disease. In contrast, those with blood type A may experience complications tied to the viral infection.

18 Jun 2020

Mutational targets of SARS-CoV-2 receptor-binding domain for vaccine-antiviral development

The COVID-19 pandemic has spread throughout the whole world within six months, causing millions of infections and hundreds of thousands of deaths. Yet there is no effective vaccine or antiviral to deal with it.

18 Jun 2020

Novel SARS-CoV-2 antibody cocktail impeccably mimics human antibody response

By using both humanized mice and convalescent patients, the researchers from the US and Singapore successfully generated non-competing and highly potent monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein that could potentially be combined to form antibody cocktails. Their groundbreaking paper is published in the leading research journal Science.

18 Jun 2020

First genome-wide CRISPR screen reveals genes that control SARS-CoV-2 infection

By performing a genome-wide CRISPR screen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), U.S. researchers identified novel proviral genes and pathways, and highlighted host genes that may regulate coronavirus disease (COVID-19) pathogenesis, as well as revealing potential targets for novel treatment approaches. Their findings are currently available on the bioRxiv* preprint server.

18 Jun 2020

Impact Biomedical's COVID-19 research published in peer-reviewed scientific journal

SGX-listed Singapore eDevelopment Limited's wholly owned subsidiary Impact Biomedical Inc. announced today that their COVID-19 research with Global Research and Discovery Group Sciences, conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc., was published in the peer-reviewed scientific journal Molecules on June 11, 2020.

18 Jun 2020

Avacta provides update on Affimer therapy for COVID-19 infection

Avacta Group plc, is pleased to announce that collaborative work with the University of Glasgow has shown that Affimer reagents prevent infection.

From Avacta Life Sciences Ltd. 18 Jun 2020

COVID-19 and blood group in aortic valve replacement

The COVID-19 pandemic has been found to cause disproportionate harm in patients with cardiovascular disease, especially among the elderly population, among other risk factors. However, a new study published on the preprint server medRxiv* in June 2020 is the first to report its clinical features in patients with aortic stenosis who have had a transcatheter aortic valve replacement (TAVR).

18 Jun 2020

COVID-19 could trigger diabetes in healthy people

The coronavirus disease (COVID-19) causes severe illness in people with underlying health conditions, such as heart disease, hypertension, lung illness, and diabetes. Now, scientists warn that viral infection may trigger the development of diabetes in healthy people.

18 Jun 2020